Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
A phase 2/3 trial testing PF-08634404 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, now recruiting.
Overview
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer is a phase 2/3 interventional study registered as NCT07392892, led by Pfizer, and recruiting when checked on 2026-09-11. Official title: A phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in treatment-naïve participants with locally advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma. Planned enrolment is 840 participants (estimated). The study started in 2026-05-14 and primary completion is expected in 2031-07-22. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares PF-08634404, Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Shares PF-08634404, Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Shares PF-08634404, Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialSSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shares PF-08634404 and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Shares Pfizer (incl. Seagen) and the tag ctgov-ingest.
- TrialA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Shares Oesophageal cancer and the tag ctgov-ingest.